Fierce Biotech January 7, 2025
A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry.
We’re maintaining the criteria we used for last year’s tracker, which means including financing rounds north of $50 million. Of course, we’ll still profile innovative new companies and larger rounds in-depth, while we focus more coverage on clinical trial results, M&A and special reports.
January
Jan. 6—Orbis Medicines
Series: A
Amount: €90 million (About $93.4 million)
Investors: NEA (New Enterprise Associates), Eli Lilly, Cormorant, the Export and Investment Fund of Denmark, and founding...
Today's Sponsors
Today's Sponsor